Clinical application of irinotecan combined with first-line chemotherapeutics against pediatric hepatoblastoma with pulmonary metastasis.
|
| Abstract |
This study aimed to investigate the short-term efficacy and adverse reactions of irinotecan combined with first-line chemotherapeutics for the treatment of pediatric hepatoblastoma with pulmonary metastasis (HB-PM). Forty-one pediatric patients with HB-PM undergoing cisplatin + fluorouracil + vincristine + doxorubicin (C5VD) treatment with bad therapeutic effect or bad response were instead treated with two cycles of an irinotecan protocol (vincristine + irinotecan + cyclophosphamide + cisplatin). The changes in recent alpha-fetoprotein (AFP), efficacy and adverse reactions in these patients were statistically analyzed. Results showed that, the median level of AFP before chemotherapy was 56432 μg/L; however, it was significantly lower (749 μg/L) after two cycles of chemotherapy (rank sum test, P = 0.00). After two cycles of chemotherapy, three patients achieved a complete response and 32 patients achieved a partial response. The recent efficacy cases accounted for 85.36% of patients (35/41). The delayed diarrhea was the most common adverse reaction to irinotecan, with an incidence rate of 58.53% (24/41), which was improved after symptomatic treatment. In conclusion, the protocol of irinotecan combined with first-line chemotherapeutics can be used for the treatment of HB-PM that is not sensitive to the C5VD protocol, with good short-term curative effect and tolerable adverse reactions.
|
|---|---|
| Authors | Huimin Hu, Weiling Zhang, Jing Li, Fan Li, Yuan Wen, Yanyan Mei, Dongsheng Huang |
| Journal | Pakistan journal of pharmaceutical sciences (Pak J Pharm Sci) Vol. 35 Issue 5 Pg. 1301-1306 (Sep 2022) ISSN: 1011-601X [Print] Pakistan |
| PMID | 36451557 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!